QuanMol Tech

QuanMol co-founder and CSO Bo Li will be attending the 2024 Gordon Research Conference on Computational Chemistry, taking place in Southern Maine from July 21-26, 2024. Let’s connect and discuss how data and computation are transforming drug discovery! #grc #grc2024 #compchem #quanmol #drugdiscovery #drugdesign #biotech #pharma #quanmoltech

Inspiring.

I just registered for LSX World Congress USA, taking place on September 11-12 2024. Join me to access strategic knowledge and form new partnerships. #LSXWorld https://lnkd.in/gtmHhxft Informa Connect

Scott L Cohen joins QuanMol as Partner/VP of Chemistry and Head of Drug Discovery With over 25 years in the biotech industry, Scott has led numerous therapeutic advancements from inception through to clinical development and commercialization. He has directed 18 discovery programs, advanced 6 compounds to the development-candidate stage, and brought 3 candidates into clinical stages. His contributions include developing ENTRESTO?(Sacubitril/Valsartan), an ARNi that benefits over 5 million heart failure patients annually, generating $6.5 billion in yearly revenue. He also achieved FDA breakthrough designation for Tipifarnib, a treatment for HRAS+ head and neck squamous cell carcinoma (HNSCC), and expedited the approval of Sohonos (Palovarotene) for fibrodysplasia ossificans progressiva (FOP) in various countries. His expertise spans oncology, rare diseases, cardiovascular, metabolism, and anti-infectives, yielding 57 granted patents. We look forward to working with Scott as we continue to build our drug discovery platform. Welcome onboard, Scott! #biotech #pharma #ai #drugdiscovery #drugdesign #drugdevelopment #quanmol #quanmoltech

QuanMol's co-founder and Chief Scientific Officer Bo Li yesterday presented how our AI-powered platform provides a technology-driven, industry-scale solution to small-molecule drug discovery. Big thanks to Q Bay Center for the invitation.

QuanMol Tech is thrilled to graduate from this year’s Endless Frontier Labs alongside an incredible cohort of innovators. We're looking forward to seeing everyone in NYC!?

?? Xingyu Shen and Bo Li will attend the SDDS 2024 Stanford Drug Discovery Symposium 04/29-04/30. Interested in how QuanMol can address your medicinal chemistry challenges? Send a LinkedIn message or email us at?[email protected]?to schedule a meeting during the symposium. #sdds #stanford #biotech #pharma #ai #drugdiscovery #drugdesign #biology #quanmol #quanmoltech

?? One-shot design of a differentiated BRD9 inhibitor using the QuanMol ReDefine platform Bromodomain-containing protein 9 (BRD9), a promising therapeutic target in cancer treatment, has been the focus of many discovery programs, including published works by Boehringer Ingelheim, GSK, AstraZeneca, and Genentech, among others. Due to its compact protein structure, developing novel inhibitors for BRD9 with a high potency poses significant challenges. QuanMol’s one-shot de novo design of a novel BRD9 inhibitor sets a new standard of in silico discovery with: ■?60 nM Potency: Validated by SPR, this represents a significant advancement over the usual micromolar activity found in virtual screenings and is even more potent than some advanced compounds. ■?Unique Scaffold & Binding Mode: Our approach introduces a novel chemical structure with differentiated binding interactions. ■?Highly Efficient Precision Design: Created precisely in just one attempt and within two hours, demonstrating our platform's capability to significantly accelerate drug discovery. At QuanMol, we aim to narrow the translational gap in small-molecule therapeutics across the industry, enhancing your R&D efficiency with our discovery solutions. This achievement with BRD9 is a testament to our mission and the capability of the AI-powered QuanMol ReDefine platform. Interested in a partnership? Let's connect at?[email protected]. #biotech #pharma #ai #drugdiscovery #drugdesign #biology #quanmol #quanmoltech